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ABSTRACT: Background. Cancer stem cells (CSCs) represent a subpo-
pulation of cells responsible for tumor growth. Their role in head and
neck squamous cell carcinoma (HNSCC) tumorigenesis and metastasis
remains uncertain.
Methods. Wound healing and an orthotopic animal model were used to
study cells expressing the CSC phenotype (CD44high and aldehyde dehy-
drogenase [ALDH]1) and assess mobility, tumorigenesis, and metasta-
sis. A prospective collection of 40 patient-derived primary HNSCC
specimens were analyzed for CSC-proportion compared to clinical
variables.
Results. CSCs exhibited significantly faster wound closure and greater
tumorigenesis and regional metastasis in vivo than non-CSCs. In primary
patient tumors, size and advanced stage were correlated with elevated
proportion of CSCs, however, not with survival.
Conclusion. HNSCC stem cells mediate tumorigenesis and regional
metastasis in vivo. In primary patient tumors, CSC-proportion was asso-
ciated with tumor size and stage, but not with metastatic spread or sur-
vival. CSC burden alone may only represent a minor variable in
understanding CSCs and metastasis. VC 2014 Wiley Periodicals, Inc.
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INTRODUCTION
In the stochastic model of tumorigenesis, all cancer cells in
a tumor population are capable of initiating tumor growth.
The cancer stem cell (CSC) theory of tumorigenesis has
recently gained popularity because of identification of a
rare subset of cells, CSCs, with the ability for self-renewal,
regeneration of a heterogeneous tumor cell population, and
the ability to initiate tumors in vivo. The CSC theory holds
that this subpopulation of cells are responsible for tumor
growth and spread, whereas non-CSCs have limited
capacity for regeneration of progeny or the ability to reca-
pitulate a tumor.1
Head and neck squamous cell carcinoma (HNSCC)
affects over 40,000 Americans with 11,000 dying annually.2
Regional lymphatic metastasis predisposes patients to the
development of distant metastasis, effectively reducing sur-
vival rates by 50%.3–6 Despite advances in treatment, over-
all survival remains static.2 Regional and distant metastases
make up a considerable proportion of the treatment fail-
ures.6 It is important to study factors associated with cancer
spread to develop more effective diagnostic techniques and
to identify therapeutic targets. Subpopulations of tumor
cells with highly tumorigenic behavior can be identified in
HNSCC based on the cellular markers CD44 and aldehyde
dehydrogenase (ALDH).7–11
CSCs have been identified in solid tumors, including
breast, prostate, and pancreatic carcinoma.11–13 We have
previously demonstrated that a subset of HNSCC cells that
express CD44 and ALDH have increased self-renewal,
tumorigenicity, and the ability to recapitulate a heterogene-
ous tumor compared with cells without these markers in a
flank injection mouse model.8,9 Cancer cells without these
markers had limited or no tumorigenic potential. Additional
work using a mouse tail vein injection model of CSC-
mediated metastasis demonstrated that HNSCC cells
expressing CD44high and ALDH1 have a greater capacity
to colonize the lungs compared to CD44low and ALDH-
tumor cells, which rarely if ever lead to successful lung
colonization.14 In addition, in vitro experiments have
shown that HNSCC stem cells have increased motility and
invasive characteristics in vitro compared to non-CSCs.14,15
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However, spontaneous metastasis from tumors initiated by
head and neck CSCs has not been shown. CSCs may play
a key role in metastasis and may serve as a novel target
for therapy. CSCs are thought to be slowly replicating cells
that have innate chemotherapy and radiation resistance
mechanisms. That behavior is a plausible mechanism for
treatment failures.12,16 Development of a physiologic model
of metastasis using CSCs is vital to demonstrate the role of
CSCs in metastasis and understand the mechanisms of
metastasis. More importantly, such a model can be used to
develop novel strategies toward cancer therapy. In this arti-
cle, we will test the hypotheses that (1) CSCs have a
greater migratory rate compared to non-CSCs in vitro, (2)
CSCs have a greater capacity for tumorigenesis and sponta-
neous metastasis using an orthotopic tip of the tongue
mouse model, and (3) CSC enrichment is associated with
metastasis and outcome.
MATERIALS AND METHODS
Patient data and tumor collection
Approval for use of patient data and specimen collec-
tion were approved by the University of Michigan’s Insti-
tutional Review Board and all patients signed written
informed consent for the study as part of the University
of Michigan Head and Neck Specialized Program of
Research Excellence. Forty patients with HNSCC were
prospectively collected from 2007 to 2012 (mean age,
57.5 years; M:F ratio, 25:15; median follow-up, 0.8
years). Primary tumors (31 oral cavity, 8 laryngeal, 1 oro-
pharyngeal) were harvested directly from tumor resection
specimens. Tumor specimens were taken directly from
the operating room and placed in 10% Dulbecco modified
Eagle’s Medium (DMEM) with 2% calf serum with
amphotericin-B. Tumors were then cut into fine pieces
with a scalpel and subjected to 2 hours of digestion with
collagenase-hyaluronidase enzyme. Specimens were then
placed into cell culture flasks with 10% DMEM and left
undisturbed for 48 hours in a cell culture incubator. Cells
were sorted by flow cytometry for CD44 expression.
Tumor CSC enrichment was determined based on the per-
centage of tumor specimen cells expressing high levels
(top 1%) of CD44 based on flow. CD44 expression per-
centage quartiles were then identified to categorize tumor
specimens for analysis. CSC enrichment and clinical cova-
riates (T and N classification, American Joint Committee
on Cancer [AJCC] stage, age, tobacco use, perineural
invasion [PNI], distant metastasis, tumor size, and tumor
depth) were analyzed. Kaplan–Meier survival statistics
were used to evaluate overall survival (OS), disease-
specific survival (DSS), and disease-free interval.
Cell lines and cell culture
UM-SCC-47 and UM-SCC-103 are well-established
HNSCC cell lines derived from advanced stage oral cavity
squamous cell carcinomas.17,18 Both cell lines were trans-
fected with a luciferase cassette (luc1) for biolumines-
cence imaging, and were grown as previously described to
70% to 80% confluency, trypsinized, and sorted by flow
cytometry for injection or plated for wound healing
assays.14
Flow cytometry
CSCs and non-CSCs were identified and sorted by flow
cytometry based on cellular expression patterns of CD44
and ALDH, as reported previously.7–9,14 ALDH activity
was identified in the UM-SCC-47-luc1 and UM-SCC-
103-luc1 cancer cell line using the ALDEFLUOR sub-
strate in accord with the manufacturer’s protocol (StemCo
Biomedical, Durham, NC). Specimens being analyzed for
ALDH activity were then counterstained with anti-CD44
(allophycocyanin conjugated; BD Pharmingen, San Diego,
CA) at the appropriate dilution. Nonviable cells are elimi-
nated using 40,6-diamidino-2-phenylindole (DAPI; BD
Pharmingen). The specific flow cytometry gates for
ALDH1 cells were set using a control sample of isolated
tumor cells in which ALDH activity was inhibited with
diethylaminobenzaldehyde. Cells expressing CD44 were
identified using a fluorescent conjugated anti-CD44 anti-
body (allophycocyanin conjugated, mouse antihuman,
clone G44-26; BD Pharmingen) at a 1:50 dilution for 15
to 20 minutes. Subsequent flow cytometry runs were used
to identify populations of cells with positive ALDH activ-
ity (ALDH1), negative ALDH activity (ALDH-) (Supple-
mental Figure 1A and 1B, online only), and cells that
express high levels of CD44 (CD44high) and low levels of
CD44 (CD44low) (Supplemental Figure 1C and 1D, online
only). For double sorts using both CD44 and ALDH,
CD44 expression was identified first followed by subse-
quent ALDH activity. Cells with CD44high/ALDH1 were
analyzed as CSC and CD44low/ALDH- were analyzed as
non-CSCs.
For the wound healing assay, UM-SCC-47-luc1 and
UM-SCC-103-luc1 were sorted by flow cytometry, as
described above for CD44 activity. Sorted cells (6 3 104
cells/well) were then placed into 24-well culture plates
with 10% Dulbecco modified Eagle’s medium and
allowed to grow to 90% to 100% confluency. A 200 uL
pipette tip was then used to make 2 parallel wounds per
well. Cells were then observed and the area of the wound
was measured at time 0, 9, 15, 18, 20, 24, 26, and 28
hours. The area of the open wound was calculated using
the NIH ImageJ free software analysis.19 Percent closure
was calculated based on the area of the wound at the
times of interest divided by the area of time 0 for each
wound. Time to 100% closure of the wound and mean
percent closure at each time point were measured.
Orthotopic mouse model
Approvals for the use of the animal model and for col-
lection of cancer specimens were obtained through the
University of Michigan’s Committee on Use and Care of
Animals and the Institutional Review Board, respectively.
Six to 8-week-old NOD/SCID mice were anesthetized
with 30–100 mg/kg ketamine and 10 mg/kg xylazine
intraperitoneal injections. UM-SCC 47 cells were then
injected into the tip of the tongue submucosally. The
range of cell numbers injected was 500–1 3 105 sorted
and unsorted cells. The animals were observed for pri-
mary tumor growth in the tip of the tongue and for
regional metastasis using bioluminescence.10 Evaluation
of successful tumor placement was determined by biolu-
minescence imaging on postinjection day number 1.
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Tumor growth at the primary site and metastasis was con-
firmed by clinical palpation and bioluminescence imag-
ing. Growth of the primary tumors and metastases were
monitored weekly for up to 12 weeks by measuring tumor
diameters with bioluminescence imaging. A partial glos-
sectomy was performed at 14 to 28 days after injection to
reduce tumor burden and improve the animal’s ability to
tolerate an oral diet and reduce upper airway obstruc-
tion.20 Glossectomy specimens were taken for histologic
analysis.
The animals were euthanized and histologic analysis of
all tumors was performed to assess gross and histologic
evidence of primary tumor growth, to confirm recapitula-
tion of a heterogeneous tumor, confirm bioluminescence
imaging regional or pulmonary metastasis, and to evaluate
for renewal of CSCs based on flow cytometry. All histol-
ogy slides were reviewed by a head and neck pathologist
(J.B.M.). Outcomes of interest were rate of tumorigenesis
(bioluminescence imaging intensity at weekly intervals),
time to regional metastasis (time from injection to first
identifiable metastasis by bioluminescence imaging), rate
of metastatic growth (bioluminescence imaging intensity
of regional metastasis at weekly intervals), and develop-
ment of distant metastasis (time from injection to identifi-
cation of distant metastasis by bioluminescence
imaging).21
Luciferase transfection and bioluminescent imaging
The cell lines used in this study were transfected with
luciferase to provide in vivo imaging to assess potential
metastasis, as previously described.7–9,14 Mice were anes-
thetized with isofluorane and placed in the bioluminescent
imaging machine to evaluate primary tumor growth and
metastasis based on total number of photons/second.22 To
control for background variation, a ratio of tumor region of
interest/background control were calculated and recorded to
assess for growth.
Primary tumor growth and metastasis in the luciferase-
transfected CSC lines injected into the mouse model was
monitored with weekly bioluminescence imaging. An area
around the tumor and metastasis as demonstrated by bio-
luminescence imaging was observed and a region of inter-
est was defined around the tumor luminescence. Total
and average photons/second were recorded and standar-
dized to background luminescence to quantify and ana-
lyze primary growth and regional metastasis for statistical
analysis.
FIGURE 1. Wound healing assay. (A) Experimental design. (B) Representative wound closure over time between CD44high and CD44low cells.
Mean percent wound closure for (C) UM-SCC-47 and (D) UM-SCC-103 cells sorted by CD44. Error bars represent standard error. [Color figure can
be viewed in the online issue, which is available at wileyonlinelibrary.com.]
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Statistical analysis
Wound-healing assays were measured based on mean
time to 100% closure and percent-closure at each individual
time point. The t test was used to calculate differences
between means. Outcome measures were bioluminescence
imaging intensity (photons/second), intensity over time
(days), and time to metastasis. Bioluminescence imaging
intensity was measured as average photons/second over
time and log-transformed for comparison. A mixed model
approach was used to test differences in intensity and dif-
ferences over time (days) between the CSC versus the non-
CSC groups. Kaplan–Meier survival statistics were used to
evaluate time to metastasis among CSCs and non-CSCs
and an unsorted control group. Patients were grouped based
on clinical covariates of interest and CD44 expression was
calculated. The t test was used to calculate differences
between means. Tumor size and CD44 expression were
then analyzed as continuous values. Pearson’s correlation
was then used to calculate correlation coefficient between
tumor size and CD44 expression. For survival analysis,
CD44 expression was grouped into CD44high and CD44low
groups based on percentile rank; 50th percentile was cal-
culated as CD44high and <50th percentile was calculated as
CD44low. Kaplan–Meier survival statistics were used to cal-
culate OS (time from definitive cancer treatment to death
of any cause), DSS (time from definitive treatment to death
from disease), and disease-free interval (time from defini-
tive treatment to recurrence of disease). Any p value < .05
was considered statistically significant.
RESULTS
In vitro analysis of cancer stem cell motility
To evaluate CSC mobility, wound healing assays were
performed using CD44high versus CD44low cells isolated
from UM-SCC-47-luc1 and UM-SCC-103-luc1 (Figure
1A). Figure 1B shows representative photographs of the
wound healing assay for UM-SCC-47 and UM-SCC-103.
Figure 1C summarizes UM-SCC-47 mean percentage of
wound closure over time. UM-SCC-47 cells sorted for
CD44high expressing cells demonstrated significantly
greater mean percentage of wound closure compared to
the CD44low expressing cells at 9, 15, 18, and 20 hours
(p 5 .0001; .001; .004; and .038, respectively). CD44high
UM-SCC-103 cells demonstrated significantly greater
mean percentage of wound closure compared to CD44low
cells at 9, 18, and 20 hours (p 5 .012; .012; and .036,
respectively; Figure 1D). The mean time to closure was
significantly shorter in cells sorted for CD44high compared
to CD44low sorted cells for both UM-SCC-47 (17.8 hours
vs 21 hours; p 5 .001) and UM-SCC-103 cell lines (20.6
hours vs 25.8 hours; p 5 .028).
Orthotopic mouse model: Tumorigenesis
An orthotopic mouse model was generated based on
previous work by Sano and Myers.18 UM-SCC-47-luc1,
1 3 105 unsorted cells were injected into the tip of the
tongue in NOD/SCID mice (Figure 2A). Tumor growth
was measured by luminescence (photons/second) at the
primary site and regional lymph nodes (Figure 2B). To
estimate the relative bioluminescence per cell, a known
number of UM-SCC-47-luc1 cells were examined for
bioluminescence intensity in vitro. Primary tumor and
lymph nodes were examined on hematoxylin-eosin–
stained sections to confirm the presence of squamous cell
carcinoma (Figure 2C).
The relative capacity of CSCs and non-CSCs to generate
tumors was compared using the orthotopic mouse model.
Tumor cells were sorted to obtain CD44high, CD44low,
CD44high/ALDH1, CD44low/ALDH-, and unsorted control
populations. To compare tumorigenic potential of CD44high
and CD44low cells, population sizes ranging from 500–
25,000 UM-SCC-47-luc1 cells/injection were analyzed.
The minimum number of cells to produce a tumor was 50-
fold lower for CD44high UM-SCC-47-luc1 cells compared
to the CD44low cells (500 vs 25,000). Furthermore, primary
tumor growth at 28 days was demonstrated in all of 5
mice injected with CD44high cells versus only 1 of 4 mice
injected with CD44low cells (p 5 .047). Similarly, there
was a greater capacity for tumor growth in mice injected
with 2.5 3 104 CD44high/ALDH1 cells compared to
CD44low/ALDH- at 28 days postinjection (2 of 2 vs 0 of 2,
respectively; Table 1). The rate of tumor take and growth
after injecting 2.5 3 104 CD44 sorted cells was signifi-
cantly higher in the CD44high and CD44high/ALDH1 popu-
lations compared to CD44low and CD44low/ALDH-
populations (p 5 .0011). Comparison of bioluminescence
at individual time points demonstrated significantly higher
levels of luminescence (photons/second) in the primary
tumors generated by CD44high and CD44high/ALDH1 cells
at days 21, 28, 36, and 43 compared to CD44low and
CD44low/ALDH- cells. Collectively, CSCs (CD44high and
CD44high/ALDH1) had significantly greater capacity for
tumorigenesis and greater rates of tumor growth compared
to non-CSCs (CD44low and CD44low/ALDH-; Figure 3A
and 3C).
Histologic evaluation of the CD44high and CD44high/
ALDH1 derived primary tumors demonstrated invasive
moderately differentiated squamous cell carcinoma with
perineural invasion (Figure 3B). These results strongly
suggest cells expressing high levels of the CSC marker
CD44 and ALDH have greater tumorigenic potential com-
pared to cells expressing CD44low or CD44low/ALDH-.
High tumorigenic potential in CD44highand CD44high/
ALDH1 cells further supports CD44 and ALDH as
markers for head and neck CSCs.
Orthotopic mouse model: Metastasis
Mice injected with 2.5 3 104 CD44high or CD44high/
ALDH1 cells were assessed for metastatic potential rela-
tive to CD44low or CD44low/ALDH- cells. All mice
injected with CD44high or CD44high/ALDH1 had a signifi-
cantly shorter metastasis-free interval compared with
mice injected with CD44low or CD44low/ALDH- cells
(mean time to metastasis 21.6 vs 40 days; p 5 .005; Fig-
ure 4A). There was significantly greater regional meta-
static luminescence in CD44high and CD44high/ALDH1
cells injections at 28, 36, and 43 days compared to
CD44low and CD44low/ALDH- (Figure 4B and 4C).
Histologic analysis of the lymph nodes confirmed the bio-
luminescence imaging results and the development of
spontaneous metastasis of squamous cell carcinoma (Fig-
ure 4D).
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A distant metastasis was detected by luminescence in a
CD44high/ALDH1 mouse that could be kept alive for 71
days postinjection and 38 days postglossectomy. Bulky
lymphadenopathy was seen by luminescence and con-
firmed by necropsy. Histologic analysis of the regional
and distant lung metastasis confirmed spontaneous metas-
tasis of squamous cell carcinoma (Figure 5E). A compara-
tive CD44low/ALDH- mouse that developed a primary
tumor significantly delayed after injection was kept alive
for a similar length of time and did not develop distant
metastasis.
Patient outcomes and tumor CD44high content
Mean CD44high content of all 40 tumor specimens was
10.8% (range, 0% to 84.5%). There was no statistical dif-
ference in mean CD44high content between subsites (oral
cavity 12.6%, oropharynx 12.9%, and larynx 3.2%; p 5
.436; Figure 5A). Mean CD44 content in primary tumors
relative to regional metastasis, distant metastasis, stage,
tumor size, and PNI was evaluated (Figure 5B–5F). Only
stage and tumor size were significantly correlated with
CD44 content. Advanced stage tumors (AJCC stage III/
IV) had significantly elevated CD44 content compared to
early stage (AJCC stage I/II; 11.6% vs 1.2%; p 5 .002).
Increased tumor size was associated with elevated CD44
content (p 5 .007). Tumor specimens from patients with
regional metastases had higher CD44high content com-
pared to patient specimens without regional metastases;
TABLE 1. Tumorigenesis: Number of primary tongue tumors resulting
from implantations of cancer stem cells (CD44high and CD44high/alde-
hyde dehydrogenase1) and non-cancer stem cells (CD44low and
CD44low/aldehyde dehydrogenase2).
Number of cells/injection CSC Non-CSC Control
1 3 105 -- -- 2/2
5 3 104 2/2 2/2 1/1
2.5 3 104 5/5 1/4 1/1
1 3 103 1/1 0/1 --
500 1/1 0/1 --
Abbreviation: CSC, cancer stem cell.
Note: Number of tumors derived from tongue injections of CSC (CD44high and CD44high/
aldehyde dehydrogenase [ALDH]1) and non-CSC (CD44low and CD44low/ALDH2) cells for
each titration of UM-SCC-47 cells.
FIGURE 2. Validation of orthotopic mouse model. (A) Gross examination of primary tongue tumor growth with palpable neck mass. Postmortem
neck dissection with visible enlarged lymph nodes (white arrows). (B) Bioluminescent imaging with high intensity (red) primary tumor and 2 areas
of increased intensity around cervical lymph nodes. (C) Hematoxylin-eosin staining demonstrates invasive moderately differentiated squamous cell
carcinoma (SCC) with perineural invasion of the primary tumor and metastatic SCC to lymph nodes. [Color figure can be viewed in the online issue,
which is available at wileyonlinelibrary.com.]
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however, this was not statistically significant (12% vs
9.7%; p 5 .70). Tumor specimens from patients who had
at least 2 years of follow-up were analyzed for associa-
tion of CD44 enrichment and distant metastases. Patients
who developed distant metastases had higher CD44 con-
tent compared to patient specimens without distant metas-
tases; however, this was not statistically significant
(10.2% vs 4.3%; p 5 .34). PNI is a known risk factor for
regional metastasis. In patients with PNI, there were
higher levels of CD44high content compared to PNI-
negative specimens; however, there was no statistical cor-
relation (10.2% and 4.3%; p 5 .32).
Analysis of patient survival outcomes relative to CD44
content was performed (Figure 5G and 5H). There was no
difference in OS, DSS, or disease-free interval (p 5 .961;
p 5 .960; and p 5 .355, respectively) among patients
with elevated CD44 enrichment compared to those with
lower CD44 content.
DISCUSSION
CSCs (CD44high and CD44high/ALDH1) have signifi-
cantly increased in vitro migration and wound healing in
an orthotopic mouse model are more tumorigenic with a
greater rate of spontaneous metastasis compared to non-
CSCs (CD44low and CD44low/ALDH-). We demonstrate a
useful orthotopic mouse model that can be used to study
in vivo tumor growth and spontaneous metastasis using a
minimal number of CSCs. Additionally, the mouse model
has shown the reproducible and reliable ability of CSCs
to form regional metastasis. These findings suggest that
CSCs (CD44high and CD44high/ALDH1) have a greater
FIGURE 3. Tumorigenesis. (A) Comparison of bioluminescence over time between cancer stem cells (CSC) (red 5 CD44high and CD44high/aldehyde
dehydrogenase [ALDH]1), non-CSC (blue 5 CD44low and CD44low/ALDH-), and unsorted control (green). (B) Gross (arrow) and histologic comparison
of CSC-derived squamous cell carcinoma (SCC) compared to primary patient tumor. (C) Representative bioluminescence imaging of CSC and non-
CSC mice at various time points. Error bars represent standard error. [Color figure can be viewed in the online issue, which is available at wileyon-
linelibrary.com.]
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capacity for spontaneous regional and distant metastatic
spread and growth compared to non-CSCs (CD44low and
CD44low/ALDH-). This is an important step in defining the
role of CSCs in metastasis and developing a model for
future targeted stem cell therapy. In primary patient
tumors, CSC enrichment in primary tumors is significantly
associated with increased tumor size and tumor stage,
whereas there were trends for association of CD44high con-
tent with regional and distant metastasis and PNI. CD44high
content was not associated with long-term survival.
Work by others in breast, colorectal, and prostate cancers
support our findings indicating that CSCs may play a criti-
cal role in tumorigenesis, treatment resistance, and metasta-
sis.11–13,23 We initially sought to evaluate in vitro assays of
cell migration via wound healing assay as a proxy to estab-
lish CSCs as a more aggressive subtype from a wound
healing standpoint. CSCs seem to have a greater rate of
wound closure compared to non-CSCs for both UM-SCC-
47 and UM-SCC-103. To further validate the in vitro data,
a more physiologic model was developed. In head and
neck cancer, previous work by Prince et al 8 and Davis
et al14 showed that UM-SCC-47-luc1 (CD44high/ALDH1)
cells have a significantly greater ability to colonize the
lungs after tail-vein injections than CD44highALDH-cells.
A common concern for the tail vein injection model is that
the lung lesions represent tumor seeding or capillary
entrapment rather than overt cancer metastasis and inva-
sion. The tip of the tongue of the orthotopic mouse model
addresses the ability for CSC recapitulation of heterogene-
ous tumors with significantly elevated tumorigenicity at
the primary site and a significant ability to form spontane-
ous regional and distant metastasis.
We have shown that cells expressing high levels of
CD44 alone or jointly with elevated ALDH activity have
FIGURE 4. Metastasis. (A) Kaplan-Meier analysis of time to regional metastasis between cancer stem cells (CSC) (red 5 CD44high and CD44high/
aldehyde dehydrogenase [ALDH]1), non-CSC (blue 5 CD44low and CD44low/ALDH-), and unsorted control (green). (B) Comparison of regional meta-
static bioluminescence imaging over time between CSC (red 5 CD44high and CD44high/ALDH1), non-CSC (blue 5 CD44low and CD44low/ALDH-), and
unsorted control (green). (C) Representative bioluminescence imaging of regional metastasis of CSC at various time points. (D) Gross (black arrow-
head) and histologic comparison of CD44high-derived spontaneous squamous cell carcinoma (SCC) metastasis. (E) Gross (white arrow) and histo-
logic comparison of CD44high/ALDH1-derived spontaneous SCC regional (white arrows) and distant metastasis (black arrows). [Color figure can be
viewed in the online issue, which is available at wileyonlinelibrary.com.]
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FIGURE 5. Association of clinical variables and CD44 enrichment in patient-derived primary tumor specimens and survival outcome analysis. CD44
enrichment relative to (A) tumor subsite (oral cavity, oropharynx, and glottis); (B) lymph node metastasis; (C) distant metastasis; (D) American Joint
Committee on Cancer stage (I/II vs III/IV); (E) perineural invasion; and (F) primary tumor size. Outcome measures of tumor specimens with elevated
CD44 enrichment (high) versus low CD44 enrichment (low). (G) Overall survival; (H) disease-specific survival; and (I) disease-free interval. [Color fig-
ure can be viewed in the online issue, which is available at wileyonlinelibrary.com.]
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a greater ability to form primary tumors and regional
metastasis compared to cells lacking these 2 markers. The
development of regional metastasis in the CSC group fur-
ther strengthens the argument that CSCs are an essential
regulator and component of metastatic spread. The exact
role of CD44 and ALDH in CSC pathophysiology
remains unclear. CD44 is a cell surface receptor for the
extracellular matrix molecule hyaluronan, with multiple
established mechanisms for cancer growth and spread.
Specifically, CD44 has been implicated as a cell surface
receptor for cell-cell adhesion, cell-matrix adhesion, endo-
thelial attachment and invasion, cell signal transmission,
and potent mediator for cell proliferation.24 Wang et al24
were able to show that elevated CD44 was associated
with worse survival. Over the last several years, its role
as a CSC marker has been extensively studied. However,
CD44high may not identify all cells with CSC characteris-
tics and has been shown to be a less selective marker of
HNSCC than ALDH expression.8 If sufficient numbers of
CD44low cells, such as the experiments in which 2.5 3
104 CD44low non-CSCs could eventually yield tumor
growth and regional metastasis over longer periods of
time compared to the CD44high CSC group, the addition
of ALDH as a second marker for CSC identification can
help demonstrate a more specific marker for CSC ability
to form primary tumors and regional metastasis.
ALDH is a well-established marker for normal hemato-
poietic and nervous system stem cells.25 In addition,
ALDH activity has been a significant marker for breast
CSCs.11 Work by Clay et al9 has shown that ALDH
activity is associated with head and neck CSCs and may
be a more specific marker for highly tumorigenic cancer
cells.8,9 Although the in vitro wound-healing assay did
not assess CD44high/ALDH1 versus CD44low/ALDH-, we
have shown that when using CD44 and ALDH as concur-
rent CSC markers, there is a greater ability for primary
tumor growth and regional metastasis compared to
CD44low/ALDH- injections. Failure to generate regional
metastasis in the CD44low/ALDH- group as compared to
the CD44low only group suggest that ALDH may be a
more specific and necessary marker for identifying CSCs
and facilitating metastasis. We did not see any gross
differences when evaluating CD44high and CD44high/
ALDH1, however, the overall group was small and sub-
group analysis would require a larger sample size. How-
ever, the exact role that ALDH plays in CSC
tumorigenicity and metastasis remains unclear. Future
work evaluating CD44high/ALDH1 versus CD44low/
ALDH- in vitro may provide a rapid model to further
investigate ALDH and CD44 concomitant expression out-
comes and potential targets for therapy. Additionally,
evaluating for differences between CD44high and
CD44high/ALDH1 in the animal model may provide addi-
tional insight into the true effect of ALDH on metastasis.
One of the weaknesses of this study was the potential
for non-CSCs to form tumors and regional metastasis.
The capacity for lymph node metastases for non-CSCs
were identified and found to be significantly lower com-
pared to CSCs. Despite attempts to isolate 100% CSCs
and 100% non-CSCs, the current flow technology does
not allow for complete cell expression or marker purity.
One can hypothesize that the lymph node growth may
represent the impurity of the non-CSC injections. Alterna-
tively, non-CSCs may have a low metastatic potential.
This question is interesting and requires future study, par-
ticularly given the heterogeneous nature of HNSCC.
Grossly, HNSCC is seen as a heterogeneous tumor with
varied clinical outcomes. At the cellular level, it is possi-
ble that although CSCs may have the potential for meta-
static spread, the CSC population in an individual tumor
is highly heterogeneous and not all CSCs are capable of
regional or distant metastasis.26 Although size and stage
were associated with enrichment of CD44high cells, there
was no statistical association with metastasis and survival.
This suggests that increased enrichment of CD44 cells is
associated with tumorigenesis, but not with metastasis
and outcome. Limitations of the patient data are the num-
ber of patients studied. A larger study may identify asso-
ciations between CD44 enrichment and metastasis and
outcome. CD44 has several variants that are associated
with survival outcomes.24 Although the antibodies used
for flow did not assess CD44-variants, it is very possible
FIGURE 6. Mechanisms of treatment failure and recurrence. (A) A single cancer stem cell (CSC) may be capable of leaving the primary tumor and
spreading to regional and distant sites. Current treatment does not fully target CSCs, thus, residual, metastatic, or resistant CSCs are responsible
for treatment failure. (B) CSC-specific treatment may lead to improved treatment. HNSCC, head and neck squamous cell carcinoma. [Color figure
can be viewed in the online issue, which is available at wileyonlinelibrary.com.]
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that CSC CD44-variant expression mediates metastatic
potential. All animals injected with UM-SCC-47 had
regional disease, whereas the patient population was not
as clear based on CD44 expression. CD44 variants, as
described by Wang et al,24 may represent a vital variable
with regard to metastatic capability. Future examination
of CD44-variant expression within CSCs may further
delineate metastatic expression signatures in CSCs. How-
ever, taken in context with the in vivo animal study find-
ings that CSCs are necessary for metastasis; one could
interpret the patient data to support the theory that a lim-
ited number of or even a single CSC is capable of form-
ing metastases and that treatment failure or recurrence
may be mediated by a small number of residual CSCs (Fig-
ure 6A). Metastatic capacity may not be programmed into
every CSC and it may be the continued accumulation of
mutations or expression alterations that may activate the
ability for particular CSCs to gain invasive capacity and to
form metastasis. Identification of the CSC-metastatic genetic
signature may yield the best chance for understanding the
CSC-specific mechanisms of metastasis and for targeted
treatment. Designing CSC-specific signatures and targets
may provide novel insight into diagnostics and potentially
novel treatment modalities (Figure 6B).
Overall, this study demonstrated the essential role
CSCs have in tumorigenesis and, more importantly, as a
vital component of the development of metastasis. The
development of an animal model with the ability to recre-
ate metastatic disease is an important step for understand-
ing the biology of CSCs and metastatic disease, but more
importantly allows for a model to test potential therapeu-
tics targeting head and neck CSCs. Further studies to bet-
ter define the role that CSCs have in tumorigenesis and
metastasis will be critical to developing novel targets for
therapy.
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